Kymera Therapeutics (KYMR) Long-Term Investments (2020 - 2026)

Kymera Therapeutics (KYMR) has 7 years of Long-Term Investments data on file, last reported at $894.7 million in Q1 2026.

• Long-Term Investments for Q1 2026 came in at $894.7 million, up 186.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $894.7 million (up 186.46% YoY), and the FY2025 annual result was $771.2 million, up 112.95% from the prior year.
• Long-Term Investments grew to $894.7 million in Q1 2026 per KYMR's latest filing, from $771.2 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $894.7 million in Q1 2026 and troughed at $61.4 million in Q1 2023.
• A 5-year average of $273.7 million and a median of $192.4 million in 2024 frame the typical range for Long-Term Investments.
• The sharpest annual moves came in 2023 and 2024: Long-Term Investments sank 59.68% in 2023, then jumped 489.84% in 2024.
• A 5-year view of Long-Term Investments shows it stood at $152.3 million in 2022, then slumped by 59.68% to $61.4 million in 2023, then jumped by 489.84% to $362.2 million in 2024, then jumped by 112.95% to $771.2 million in 2025, then grew by 16.02% to $894.7 million in 2026.
• Business Quant data shows KYMR's Long-Term Investments at $894.7 million in Q1 2026, $771.2 million in Q4 2025, and $473.1 million in Q3 2025.